References
  1. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432-450.
  2. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group. A randomized multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004;21:109-19
  3. Lopez E, Gascoin G, Flamant C, Merhi M, Tourneux P, Baud O, et al. Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future? BMC Pediatr 2013;13:165
  4. Tridente A, De Martino L, De Luca D. Porcine vs bovine surfactant therapy for preterm neonates with RDS: systematic review with biological plausibility and pragmatic meta-analysis of respiratory outcomes. Respir Res 2019;20:28
  5. Sánchez Luna M, Bacher P, Unnebrink K, Martinez-Tristani M, Ramos Navarro C. Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials. J Perinatol. 2020 Aug;40(8):1121-1134.
  6. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 2001; 163, 1723–1729
  7. Singh N, Halliday HL, Stevens TP, Suresh G, Soll R, Rojas-Reyes MX. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2015;12: CD010249
  8. Lanciotti L, Correani A, Pasqualini M, Antognoli L, Dell’Orto VG, Giorgetti C, et al. respiratory distress syndrome in preterm infants of less than 32 weeks: what difference does giving 100 or 200 mg/kg of exogenous surfactant make? Pediatr Pulmonol. 2022 May 16; 57(9): 2067–73.
  9. Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M, et al. Comparative effectiveness of surfactant preparations in premature infants. J Pediatr. 2013;163:955–60. E951.
  10. Ramanathan R, Bhatia JJ, Sekar K, Ernst FR. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study. J Perinatol. 2013;33:119–25.
  11. Paul S, Rao S, Kohan R, McMichael J, French N, Zhang G, et al. Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: a retrospective cohort study. J Paediatr Child Health. 2013;49:839–44.
  12. Naseh A, Yekta BG. INSURE method (INtubation-SURfactant- Extubation) in early and late premature neonates with respiratory distress: factors affecting the outcome and survival rate. Turk J Pediatr. 2014;56:232–7.
  13. Goss KCW, Gale C, Malone R, Longford N, Ratcliffe K, Modi N. Effect of surfactant dose on outcomes in preterm infants with respiratory distress syndrome: the OPTI-SURF study protocol. BMJ Open 2020;10:e038959.
  14. Magni T, Ragni C, Pelizzi N, Sharma S, Perez-Kempner L, Turkstra E et al. Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review. Pharmacoecon Open. 2023 May;7(3):359-371.
  15. Mussavi M, Mirnia K, Asadollahi K. Comparison of the efficacy of three natural surfactants (Curosurf, Survanta, and Alveofact) in the treatment of respiratory distress syndrome among neonates: a randomized controlled trial. Iran J Pediatr. 2016;26: e5743.
  16. Najafian B, Karimi-Sari H, Khosravi MH, Nikjoo N, Amin S, Shohrati M. Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: a randomized clinical trial. Contemp Clin Trials Commun. 2016; 3:55–9.
  17. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016; 375:2293–7.
  18. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RHet al. Bronchopulmonary dysplasia. Nat Rev Dis Primers2019; 5, 78
  19. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967 Feb 16;276(7):357-68.
  20. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988 Oct;82(4):527-32.
  21. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004; 114, 1305–1311
  22. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV et al. Bronchopulmonary dysplasia: executive summary of a workshop. J. Pediatr. 2018; 197, 300–308
  23. Isayama T, Lee SK, Yang J, Lee D, Daspal S, Dunn M et al. Revisiting the definition of bronchopulmonary dysplasia: effect of changing panoply of respiratory support for preterm neonates. JAMA Pediatr. 2017; 171, 271–279.
  24. Svedenkrans J, Stoecklin B, Jones JG, Doherty DA, Pillow JJ. Physiology and Predictors of Impaired Gas Exchange in Infants with Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2019 Aug 15;200(4):471-480.
  25. Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants: an evidence- based approach. Am. J. Respir. Crit. Care Med. 2019; 200, 751–759.